Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy

Table 4 Clinical characteristics according to occurrence of early rebleeding event (mean ± SD) n (%)

	No rebleeding(n = 88)	Rebleeding(n = 13)	Total(n = 101)	P value
Sex (male)	27 (30.7)	5 (38.5)	32 (31.7)	0.574
Age (yr)	64.25 ± 17.40	69.0 ± 13.97	64.86 ± 17.01	0.350
Hemodynamic shock	46 (52.3)	7 (53.8)	53 (52.5)	0.916
Helicobacter infection	19 (21.6)	3 (23.1)	22 (21.8)	0.904
Hemoglobin (g/dL)	8.61 ± 2.77	7.09 ± 2.02	8.41 ± 2.72	0.060
Hemoglobin < 7 g/dL	26 (29.5)	7 (53.8)	33 (32.7)	0.081
Blood urea nitrogen (mg/dL)	39.81 ± 25.92	40.09 ± 33.50	39.84 ± 26.82	0.972
Creatinine (mg/dL)	1.26 ± 1.12	1.03 ± 0.83	1.23 ± 1.09	0.473
Albumin (g/dL)	2.97 ± 0.60	2.86 ± 0.47	2.96 ± 0.59	0.532
Type 2 diabetes mellitus	21 (23.9)	3 (23.1)	24 (23.8)	0.950
Hypertension	38 (43.2)	3 (23.1)	41 (40.6)	0.168
Heart failure	9 (10.2)	2 (15.4)	11 (10.9)	0.577
Ischemic heart disease	17 (19.3)	1 (7.7)	18 (17.8)	0.454
Antiplatelet medication	37 (42.0)	7 (53.8)	44 (43.6)	0.423
NSAID	7 (8.0)	2 (15.4)	9 (8.9)	0.380
Multiple antiplatelet medications	5 (5.7)	2 (15.4)	7 (6.9)	0.221
Steroid	5 (5.7)	1 (7.7)	6 (5.9)	0.572
Melena	50 (56.8)	9 (69.2)	59 (58.4)	0.397
Hematemesis	51 (58.0)	4 (30.8)	55 (54.5)	0.066
Hematochezia	5 (5.7)	2 (15.4)	7 (6.9)	0.199
Complete Rockall score	6.73 ± 1.40	7.69 ± 1.03	6.86 ± 1.39	0.020
Rockall score > 6	43 (48.9)	12 (92.3)	55 (54.5)	0.003
Somatostatin use	41 (46.6)	8 (61.5)	49 (48.5)	0.314

NSAID: Non-steroidal anti-inflammatory drug.